



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letters to the editor

E-Cigarette Use and COVID-19: Questioning Data Reliability



To the Editors:

We read with interest the study by Gaiha et al. [1] which examined the association between e-cigarette use and COVID-19. The authors found a statistically significant association between ever, but not current, e-cigarette use and COVID-19. It is not biologically plausible that e-cigarette trial or experimentation would cause effects that result in stronger predisposition to COVID-19 than current/regular use. Therefore, no causal link between e-cigarette use and COVID-19 can be implied. While the high proportion of ever e-cigarette users who were reportedly tested for COVID-19 could explain the high rate of COVID-19 diagnosis, the reliability of participants' responses is questionable. In accordance with the Centers for Disease Control and Prevention (CDC), 7,362,526 COVID-19 tests were performed in the U.S. population from March 1 to May 16 (2 days after survey completion) [2]. A weighted proportion of 35.4% of adolescents aged 13–17 years (NYTS 2019) and 25.8% of Americans aged 18–24 years were ever e-cigarette users [3]. The total population of these age groups in the U.S. was derived from U.S. Census Bureau data (2018) [4], and was estimated at 20,818,953 aged 13–17 years and 30,373,478 aged 18–24 years (with 7,369,909 and 7,836,357 being ever e-cigarette users, respectively). Thus, the proportion of ever and never e-cigarette users who were tested for COVID-19, according to the study by Gaiha et al. [1], translates to 4,712,308 tests performed in age group 13–24 years (2,661,097 tests in ever and 2,051,211 tests in never e-cigarette users). This represents 64.0% of all tests performed in the U.S. until May 16, a gross overestimation considering the inadequate testing capacity at that time and the strong priority given to people at risk for severe COVID-19. The CDC reports that less than 5% of COVID-19 tests were performed in children <18 years of age [2]. Thus, the findings by Gaiha et al. [1] are almost certainly based on false reports by the participants. Finally, the proportion of participants aged 13–24 years who reported having a diagnosis of COVID-19 would represent 46.8% of all U.S. confirmed cases until May 14 [5], which is probably another gross overestimation.

In conclusion, the findings by Gaiha et al. [1] cannot be considered valid and population representative, probably due to

serious response bias and the approach of adjusting an online convenience sample to a population-based sample through weighting. In addition, the link between ever, but not current, e-cigarette use and COVID-19 suffers from biological implausibility. The authors should probably reconsider the conclusions and interpretation of their study as presented in the manuscript and the accompanying press release.

Konstantinos Farsalinos, M.D., M.P.H.
Department of Pharmacy
University of Patras
Rio, Greece

Department of Public and Community Health
School of Public Health
University of West Attica
Athens, Greece

Raymond Niaura, Ph.D.
Departments of Social and Behavioral Science and Epidemiology
College of Global Public Health
New York University
New York City, New York

References

- [1] Gaiha SM, Cheng J, Halpern-Felsher B. Association between youth smoking, electronic cigarette use, and COVID-19. *J Adolesc Health* 2020;67:519–23.
- [2] Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-19). COVID view summary ending on May 16, 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/05222020.html>. Accessed August 14, 2020.
- [3] Centers for Disease Control and Prevention (CDC). Electronic cigarette use among U.S. adults, 2018. Available at: <https://www.cdc.gov/nchs/products/databriefs/db365.htm>. Accessed August 14, 2020.
- [4] United States Census Bureau. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2019. Available at: <https://www2.census.gov/programs-surveys/popest/technical-documentation/file-layouts/2010-2019/nc-est2019-agesex-res.csv>. Accessed August 14, 2020.
- [5] World Health Organization. COVID-19 dashboard. United States of America. Available at: <https://covid19.who.int/region/amro/country/us>. Accessed August 24, 2020.

Conflicts of Interest: Konstantinos Farsalinos has no conflict of interest to report for the past 5 years. Before that, two studies (published in 2014 and 2015) were funded by the non-profit association AEMSA (funding in 2013) and one study (published in 2016) was funded by the non-profit association Tennessee Smoke-free Association (funding in 2015). Raymond Niaura receives funding from the Food and Drug Administration Center for Tobacco Products via contractual mechanisms with Westat and the National Institutes of Health.